HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults

References

• Cohen SM, Van Handel MM, Branson BM et al. Vital signs: HIV prevention through care and treatment – United States. Morb. Mortal. Wkly Rep.60(47), 1618–1623 (2011).
   PubMedGoogle Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med.352(1), 48–62 (2005).
   PubMed Web of Science ®Google Scholar
• Caron-Debarle M, Boccara F, Lagathu C et al. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr. Pharm. Des.16(30), 3352–3360 (2010).
   PubMed Web of Science ®Google Scholar
• Galli M, Ridolfo AL, Adorni F et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J. Acquir. Immun. Defic. Syndr.29(1), 21–31 (2002).
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS17(8), 1179–1193 (2003).
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med.356(17), 1723–1735 (2007).
   PubMed Web of Science ®Google Scholar
• Annamalia L, Westmoreland SV, Domingues HG, Walsh DG, Gonzalez RG, O’Neil SP. Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleoside reverse transcriptase inhibitors. PLos ONE5(12), E14429 (2010).
   PubMedGoogle Scholar
• Reinsch N, Neuhaus K, Esser S et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur. J. Prev. Cardiolog.19(2), 267–274 (2012).
   PubMed Web of Science ®Google Scholar
• Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur. Heart J.33(7), 866–874 (2012).
   PubMed Web of Science ®Google Scholar
• Mondy KE, Gottdiener J, Overton ET et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin. Infect. Dis.52(3), 378–386 (2011).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE. The cardiovascular manifestations of HIV infection. Dialogues Cardiovasc. Med.12(1), 5 (2007).
   Google Scholar
• Fisher SD, Lipshultz SE. Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann. NY Acad. Sci.946, 13–22 (2001).
   PubMed Web of Science ®Google Scholar
• Butt AA, Chang CC, Kuller L et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch. Intern. Med.171(8), 737–743 (2011).
   PubMedGoogle Scholar
• Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med.342(15), 1077–1084 (2000).
   PubMed Web of Science ®Google Scholar
• Herskowitz A, Wu TC, Willoughby SB et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J. Am. Coll. Cardiol.24(4), 1025–1032 (1994).
   PubMedGoogle Scholar
• Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS17(Suppl. 1), S96–S122 (2003).
   PubMedGoogle Scholar
• Wever Pinzon O, Silva Enciso J, Romero J et al. Risk stratification and prognosis of human immunodificiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography. Circ. Cardiovasc. Imag.4(4), 363–370 (2011).
   PubMedGoogle Scholar
• Wever Pinzon O, Bangalore S, Romero J, Silva Enciso J, Chaudhry FA. Inotropic contractile reserve can risk-stratify patients with HIV cardiomyopathy a dobutamine stress echocardiography study. JACC Cardiovasc. Imag.4(12), 1231–1238 (2011).
   PubMedGoogle Scholar
• Carrillo-Jimenez R, Treadwell TL, Goldfine H, Buenano A, Lamas GA, Hennekens CH. Brain natriuretic peptide and HIV-related cardiomyopathy. AIDS Read.12(11), 501–503, 508 (2002).
   PubMedGoogle Scholar
• Duprez DA, Neuhaus J, Tracy R et al. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS25(5), 651–657 (2011).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Fox CH, Perez-Atayde AR et al. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. Am. J. Cardiol.66(2), 246–250 (1990).
   PubMedGoogle Scholar
• Orenstein JM. Replication of HIV-1 in vivo and in vitro. Ultrastruct. Pathol.31(2), 151–167 (2007).
   PubMed Web of Science ®Google Scholar
• Reinsch N, Neuhaus K, Esser S et al. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin. Trials11(3), 156–162 (2010).
   PubMed Web of Science ®Google Scholar
• Nayak G, Ferguson M, Tribble DR et al. Cardiac diastolic dysfunction is prevalent in HIV-infected patients. AIDS Patient Care STDS23(4), 231–238 (2009).
   PubMed Web of Science ®Google Scholar
• Luo L, Ye Y, Liu Z et al. Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China. Int. J. STD AIDS21(12), 814–818 (2010).
   PubMedGoogle Scholar
• Grandi AM, Nicolini E, Giola M et al. Left ventricular remodelling in asymptomatic HIV infection on chronic HAART: comparison between hypertensive and normotensive subjects with and without HIV infection. J. Hum. Hypertens. doi:10.1038/jhh.2011.81 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Seoane L, Shellito J, Welsh D, De Boisblanc BP. Pulmonary hypertension associated with HIV infection. South Med. J.94(6), 635–639 (2001).
   PubMed Web of Science ®Google Scholar
• Limsukon A, Saeed AI, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J. Med.73(7), 1037–1044 (2006).
   PubMedGoogle Scholar
• Nunes H, Humbert M, Sitbon O et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.167(10), 1433–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Fisher SD, Lipshultz SE. Cardiovascular abnormalities in HIV-infected individuals. In: Braunwald’s Heart Disease. A Textbook of Cardiovascular Medicine (Ninth Edition and Electronic Edition.) Bonow RO, Libby P, Mann DL, Zipes DP, Braunwald E (Eds). Elsevier Saunders, PA, USA, 1618–1627 (2011).
   Google Scholar
• Heidenreich PA, Eisenberg MJ, Kee LL et al. Pericardial effusion in AIDS. Incidence and survival. Circulation92(11), 3229–3234 (1995).
   PubMed Web of Science ®Google Scholar
• Lind A, Reinsch N, Neuhaus K et al. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur. J. Med. Res.16(11), 480–483 (2011).
   PubMed Web of Science ®Google Scholar
• Nanavati KA, Fisher SD, Miller TL, Lipshultz SE. HIV-related cardiovascular disease and drug interactions. Am. J. Cardiovasc. Drugs4(5), 315–324 (2004).
   PubMedGoogle Scholar
• Askgaard G, Kristoffersen US, Mehlsen J, Kronborg G, Kjaer A, Lebech AM. Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol. PLoS ONE6(5), E20196 (2011).
   PubMedGoogle Scholar
• Lipshultz SE, Orav EJ, Sanders SP, Hale AR, Mcintosh K, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N. Engl. J. Med.327(18), 1260–1265 (1992).
   PubMedGoogle Scholar
• Mikhail IJ, Purdy JB, Dimock DS et al. High rate of coronary artery abnormalities in adolescents and young adults infected with human immunodeficiency virus early in life. Pediatr. Infect. Dis. J.30(8), 710–712 (2011).
   PubMedGoogle Scholar
• Lipshultz SE, Easley KA, Orav EJ et al. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection (P2C2 HIV) Study Group. Circulation102(13), 1542–1548 (2000).
   PubMed Web of Science ®Google Scholar
• Fisher SD, Easley KA, Orav EJ et al. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV multicenter study. Am. Heart J.150(3), 439–447 (2005).
   PubMed Web of Science ®Google Scholar
• Luginbuhl LM, Orav EJ, Mcintosh K, Lipshultz SE. Cardiac morbidity and related mortality in children with HIV infection. JAMA269(22), 2869–2875 (1993).
   PubMedGoogle Scholar
• Al-Attar I, Orav EJ, Exil V, Vlach SA, Lipshultz SE. Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J. Am. Coll. Cardiol.41(9), 1598–1605 (2003).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Orav EJ, Sanders SP, Colan SD. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation92(8), 2220–2225 (1995).
   PubMed Web of Science ®Google Scholar
• Dube MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation118(2), E36–E40 (2008).
   PubMedGoogle Scholar
• Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am. Heart J.151(6), 1147–1155 (2006).
   PubMed Web of Science ®Google Scholar
• Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J. Infect. Dis.185(4), 456–462 (2002).
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Komarow L, Parker RA et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s. J. Am. Coll. Cardiol.52(7), 569–576 (2008).
   PubMed Web of Science ®Google Scholar
• Ross AC, Storer N, O’Riordan MA, Dogra V, McComsey GA. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr. Infect. Dis. J.29(7), 634–638 (2010).
   PubMedGoogle Scholar
• Ross AC, O’Riordan MA, Storer N, Dogra V, McComsey GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis211(2), 492–498 (2010).
   PubMed Web of Science ®Google Scholar
• Charakida M, Donald AE, Green H et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation112(1), 103–109 (2005).
   PubMed Web of Science ®Google Scholar
• Miller TL, Somarriba G, Orav EJ et al. Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. J. Acquir. Immun. Defic. Syndr.55(2), 182–188 (2010).
   PubMedGoogle Scholar
• Miller T, Borkowsky W, Dimeglio L et al. Pediatric HIV/AIDS Cohort Study (PHACS). Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med.13(5), 264–275 (2011).
   PubMedGoogle Scholar
• Conaldi PG, Serra C, Dolei A et al. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1β plus tumor necrosis factor-α. J. Med. Virol.47(4), 355–363 (1995).
   PubMed Web of Science ®Google Scholar
• Ren Z, Yao Q, Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab. Invest.82(3), 245–255 (2002).
   PubMed Web of Science ®Google Scholar
• Bukrinsky M, Sviridov D. Human immunodeficiency virus infection and macrophage cholesterol metabolism. J. Leukoc. Biol.80(5), 1044–1051 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Johnson RM, Saha C et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. AIDS22(5), 653–655 (2008).
   PubMedGoogle Scholar
• Fisher SD, Kanda BS, Miller TL, Lipshultz SE. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. Am. J. Cardiovasc. Drugs11(6), 383–394 (2011).
   PubMedGoogle Scholar
• Fitch K, Grinspoon S. Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. Am. J. Clin. Nut.94(6), 1721S–1728S (2011).
   PubMedGoogle Scholar
• Lewis W, Kohler JJ, Hosseini SH et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol γ hypothesis. AIDS20(5), 675–684 (2006).
   PubMed Web of Science ®Google Scholar
• Gerschenson M, Erhart SW, Paik CY et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3´-azido-3´-deoxythymidine. AIDS Res. Hum. Retroviruses16(7), 635–644 (2000).
   PubMed Web of Science ®Google Scholar
• Gerschenson M, Poirier MC. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann. NY Acad Sci.918, 269–281 (2000).
   PubMed Web of Science ®Google Scholar
• Torres SM, March TH, Carter MM et al.In utero exposure of female CD-1 mice to AZT and/or 3TC: I. persistence of microscopic lesions in cardiac tissue. Cardiovasc. Toxicol.10(1), 37–50 (2010).
   PubMedGoogle Scholar
• Torres SM, Divi RL, Walker DM et al.In utero exposure of female CD-1 mice to AZT and/or 3TC: II. persistence of functional alterations in cardiac tissue. Cardiovasc. Toxicol.10(2), 87–99 (2010).
   PubMed Web of Science ®Google Scholar
• Chan SS, Santos JH, Meyer JN et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ. Mol. Mutagen.48(3–4), 190–200 (2007).
   PubMedGoogle Scholar
• D’Ascenzo F, Cerrato E, Biondi-Zoccai G et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur. Heart. J.33(7), 875–880 (2012).
   PubMedGoogle Scholar
• Yan Q. Acute effects of HIV protease inhibitors on the failing heart. Antiviral. Ther.11(Suppl. 3), L11 (2006).
   Google Scholar
• Hunt K, Hughes CA, Hills-Nieminen C. Protease inhibitor-associated QT interval prolongation. Ann. Pharmacother.45(12), 1544–1550 (2011).
   PubMedGoogle Scholar
• Charbit B, Gayat E, Voiriot P, Boccara F, Girard PM, Funck-Brentano C. Effects of HIV protease inhibitors on cardiac conduction velocity in unselected HIV-infected patients. Clin. Pharmacol. Ther.90(3), 442–448 (2011).
   PubMedGoogle Scholar
• Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case–control study using Quebec’s public health insurance database (RAMQ). J. Acquir. Immun. Defic. Syndr.57(3), 245–253 (2011).
   PubMed Web of Science ®Google Scholar
• Ding X, Andraca-Carrera E, Cooper C et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. Presented at: The 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, USA, 27 February–2 March 2011.
   Google Scholar
• Cruciani M, Zanichelli V, Serpelloni G et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS25(16), 1993–2004 (2011).
   PubMed Web of Science ®Google Scholar
• Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS25(10), 1289–1298 (2011).
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Neuhaus J, Babiker A et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS22(4), F17–F24 (2008).
   PubMedGoogle Scholar
• Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS12(7), F51–F58 (1998).
   PubMed Web of Science ®Google Scholar
• Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J. Acquir. Immun. Defic. Syndr.49(Suppl. 2), S79–S85 (2008).
   PubMed Web of Science ®Google Scholar
• Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr. Diab. Rep.9(1), 37–42 (2009).
   PubMed Web of Science ®Google Scholar
• Feeney ER, Mallon PW. HIV and HAART-associated dyslipidemia. Open. Cardiovasc. Med. J.5, 49–63 (2011).
   PubMedGoogle Scholar
• Worm SW, De Wit S, Weber R et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D Study). Circulation119(6), 805–811 (2009).
   PubMed Web of Science ®Google Scholar
• Butt AA. HIV infection and the risk of diabetes mellitus. AIDS23(10), 1227–1234 (2009).
   PubMed Web of Science ®Google Scholar
• Miller TL, Orav EJ, Lipshultz SE et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J. Pediatr.153(4), 491–497 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Patel K, Siberry GK et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the pediatric HIV/AIDS cohort study. Am. J. Clin. Nut.94, 1485–1495 (2011).
   PubMed Web of Science ®Google Scholar
• Werner ML, Pone MV, Fonseca VM, Chaves CR. Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy. J. Pediatr. (Rio J.)86(1), 27–32 (2010).
   PubMedGoogle Scholar
• Hurwitz BE, Klimas NG, Llabre MM et al. HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: role of protease inhibitor exposure. Cardiovasc. Toxicol.4(3), 303–316 (2004).
   PubMedGoogle Scholar
• Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet369(9568), 1169–1178 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin. Infect. Dis.48(8), 1123–1128 (2009).
   PubMedGoogle Scholar
• Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med.359(14), 1429–1441 (2008).
   PubMed Web of Science ®Google Scholar
• Macinnes A, Lazzarin A, Di Perri G et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin. Trials12(1), 24–36 (2011).
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat. Rev. Drug Discov.10(2), 95–96 (2011).
   PubMedGoogle Scholar
• Fitch K, Abbara S, Lee H et al. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS26(5), 587–597 (2012).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE. Increased left ventricular and aortic dimensions in long-term multiagent antiretroviral therapy (ART)-treated HIV-infected children: the NIH multicenter pediatric HIV/AIDS Cohort Study (PHACS). Circulation120(Suppl. 18), S909 (2009).
   Google Scholar
• Connor EM, Sperling RS, Gelber R et al. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med.331(18), 1173–1180 (1994).
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Mcintyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet355(9222), 2237–2244 (2000).
   PubMed Web of Science ®Google Scholar
• Knapp KM, Brogly SB, Muenz DG et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr. Infect. Dis. J.31(2), 164–170 (2012).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Shearer WT, Thompson B et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART therapy in HIV-Exposed Infants and Children Cohort Study). J. Am. Coll. Cardiol.57(1), 76–85 (2011).
   PubMed Web of Science ®Google Scholar
• Mas CM, Miller TL, Cordero C et al. The effects of fetal and childhood exposure to antiretroviral agents. J. AIDS Clinic. Res. doi:10.4172/21556-113.S20-01 (2011) (Epub ahead of print).
   Google Scholar
• Lipshultz SE. Association of cardiac structure and function with in utero antiretroviral exposure among uninfected children born to HIV-infected mothers in the pediatric HIV/AIDS cohort study. Circulation122(Suppl. 21), A16026 (2010).
   Google Scholar
• Lipshultz SE, Easley KA, Orav EJ et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection study group. N. Engl. J. Med.343(11), 759–766 (2000).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE. Antiretroviral therapy (ART) cardiac effects in HIV-infected children: the multicenter NHLBI Cardiac Highly Active Antiretroviral Therapy (CHAART-II) Study. Circulation120(Suppl. 18), S909 (2009).
   Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med.324(12), 808–815 (1991).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol.11(10), 950–961 (2010).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE. Ventricular dysfunction clinical research in infants, children and adolescents. Prog. Pediatr. Cardiol.12(1), 1–28 (2000).
   PubMedGoogle Scholar
• Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation104(3), 257–262 (2001).
   PubMed Web of Science ®Google Scholar
• Solages A, Vita JA, Thornton DJ et al. Endothelial function in HIV-infected persons. Clin. Infect. Dis.42(9), 1325–1332 (2006).
   PubMed Web of Science ®Google Scholar
• Dube MP. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin. Infect. Dis.47(4), 567–574 (2008).
   PubMed Web of Science ®Google Scholar
• Baker JV, Henry WK, Patel P et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin. Infect. Dis.53(8), 826–835 (2011).
   PubMed Web of Science ®Google Scholar
• Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J. Acquir. Immune Defic. Syndr.39(2), 152–158 (2005).
   PubMed Web of Science ®Google Scholar
• Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA. Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc. Toxicol.4(2), 199–206 (2004).
   PubMedGoogle Scholar
• Dressman J, Kincer J, Matveev SV et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest.111(3), 389–397 (2003).
   PubMed Web of Science ®Google Scholar
• Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J. Acquir. Immune Defic. Syndr.44(5), 493–499 (2007).
   PubMed Web of Science ®Google Scholar
• Kappert K, Leppanen O, Paulsson J et al. Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury. J. Acquir. Immune Defic. Syndr.43(4), 383–392 (2006).
   PubMedGoogle Scholar
• Sutliff RL, Dikalov S, Weiss D et al. Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am. J. Physiol. Heart Circ. Physiol.283(6), H2363–H2370 (2002).
   PubMedGoogle Scholar
• Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology76(5), 444–450 (2011).
   PubMed Web of Science ®Google Scholar
• Rasmussen LD, Engsig FN, Christensen H et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS25, 1637–1646 (2011).
   PubMed Web of Science ®Google Scholar
• Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin. Infect. Dis.53(1), 84–91 (2011).
   PubMed Web of Science ®Google Scholar
• Ferraioli G, Tinelli C, Maggi P et al. Arterial stiffness evaluation in HIV-positive patients: a multicenter matched control study. AJR Am. J. Roentgenol.197(5), 1258–1262 (2011).
   PubMedGoogle Scholar
• Maggi P, Serio G, Epifani G et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS14(16), F123–F128 (2000).
   PubMed Web of Science ®Google Scholar
• Hsue PY, Ordovas K, Lee T et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am. J. Cardiol.109(5), 742–747 (2012).
   PubMedGoogle Scholar
• Lorenz MW, Stephan C, Harmjanz A et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis196(2), 720–726 (2008).
   PubMed Web of Science ®Google Scholar
• Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin. Pharmacother.12(1), 31–46 (2011).
   PubMed Web of Science ®Google Scholar
• Triant VA, Josephson F, Rochester CG et al. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin. Infect. Dis.54(3), 408–413 (2011).
   PubMedGoogle Scholar